Metyrapone

DB01011ApprovedInvestigationalSmall moleculeSteroid Synthesis Inhibitors

Metyrapone is a steroid 11-beta-monooxygenase inhibitor used to test hypothalamic-pituitary ACTH function. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome.

Chemical structure of Metyrapone
Mechanism
Curator reviewed
Primary indication
Used as a diagnostic drug for testing hypothalamic-pituitary ACTH function.Curator reviewed · 1 structured indication
Formula / weight
C14H14N2O · 226.2738 g/mol (avg)
First approval
United States, 1962
Brand names
  • Metopirone

Resolves to

Structure
InChIKeyFJLBFSROUSIWMA-UHFFFAOYSA-NSMILESCC(C)(C(=O)C1=CN=CC=C1)C1=CC=CN=C1
Transporters

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
952Drug interactionsStructured to mechanism, not free text
Sign in
25Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
1ContraindicationEach with its own population and attribute set
Sign in
6Marketed productsAcross 3 countries and 4 labellers
Sign in
1ATC codeIncluding every combination product, plus 20 drug categories
Sign in
27+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Metyrapone, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account